Willkie Farr & Gallagher advised Insight Partners on the deal, and Ropes & Gray advised HarbourVest Partners. Insight Partners announced the closing of Continuation Fund III,...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Bain Capital Life Sciences in the transaction. Serán Bioscience (“Serán”), a leading contract development and manufacturing organization (CDMO), announced a strategic growth...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Vir Biotechnology in the transaction. Vir Biotechnology (Nasdaq: VIR) announced it has entered into an exclusive worldwide license agreement with Sanofi for...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Novavax Inc. in the transaction. Novavax Inc.(Nasdaq: NVAX) announced it has entered into a co-exclusive licensing agreement with French pharmaceutical company Sanofi...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Chiesi Group on the transaction, and Latham & Watkins advised Gossamer Bio. Chiesi Group announced it has entered into a global collaboration...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Eversource Energy in the transaction. Eversource Energy (NYSE: ES) (“Eversource”) announced its definitive agreement to sell its 50 percent ownership stake in the 924-megawatt Sunrise Wind project...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Crosspoint Capital Partners on the deal. Crosspoint Capital Partners acted as leading investor in a €65 million Series A follow-on funding round...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised H.I.G.Infrastructure on the deal. H.I.G.Infrastructure, an affiliate of H.I.G. Capital, announced the acquisition of Tower Engineering Professionals, Inc. (TEP), a leading full-service provider...
You must be a Standard 1 Year member to access this content.
Goodwin advised TCR² Therapeutics Inc. on the deal while Ropes & Gray represented Adaptimmune Therapeutics plc. TCR² Therapeutics Inc. (NASDAQ: TCRR) announced its definitive agreement with Adaptimmune...
You must be a Standard 1 Year member to access this content.
Cooley advised Redx Pharma on the deal while Ropes & Gray has advised Jounce Therapeutics, Inc. Redx Pharma, a UK clinical-stage biotechnology company, announced its all share...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented HUTCHMED on the deal. HUTCHMED (China) Limited and its subsidiary, HUTCHMED Limited announced an exclusive worldwide license agreement with Japan’s largest drugmaker Takeda...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Advent International on the deal. Advent International closed a $175 million minority investment in TredenceInc., a data science and AI engineering company. The...
You must be a Standard 1 Year member to access this content.
